NCT01958775

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study A) 2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)

Detailed description

Study A: Using constant feeding with a nasoduodenal tube and stable isotope infusion, mathematical modelling will be utilised to measure lipoprotein production and clearance. The lipoproteins assessed will be apoB-100 from the liver and apoB-48 from the intestine. StudyB: Volunteers will be given a liquid meal with retinyl palmitate (vitamin A) to label chylomicrons made from the meal. 7 hours later they will be given GLP-2 or placebo. Measurements of plasma and TRL(triglyceride rich lipoprotein) triglyceride and TRL retinyl palmitate will be carried out to see whether GLP-2 increases these parameters.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	GLP-2	single subcutaneous dose of 1500mcg
DRUG	Placebo

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2013-10-09
• Last updated: 2015-03-10

Locations

1 site across 1 country: Canada